

WELCOME to the Cannabis in the Workplace: An ECHO on Health, Safety, and Management

June 11 – August 29, 2025









Series Learning Objectives

After participating in this activity, learners will be able to:

- 1. Describe the potential impacts of cannabis on individual health and workplace health and safety
- 2. Recognize cannabis-related impairment and intervene to support health and safety in the workplace and the health of the involved individual
- 3. Describe legal and regulatory policies at state and national level that shape management of cannabis in the workplace
- 4. Develop and implement workplace policies related to cannabis that support health and safety



Series Sessions

Date	Session Title
6/11/2025	Pharmacology of cannabis and impact on individual
6/25/2025	Impact of cannabis on workplace
7/9/2025	Cannabis testing
7/23/2025	Assessing impairment in the workplace
8/6/2025	Intervention, management of leave, treatment, re-entry into the workplace
8/20/2025	The legal and regulatory landscape
8/27/2025*	Development of workplace policies



Core Panel

Bob McLellan, MD, MPH Charla Stevens, JD Claire Bryant, MPH Dana Lariviere Jackie Pogue, MPH Jeanne Venuti, BS

Liz Bailey, JD Luke Archibald, MD Seddon Savage, MD Occupational Medicine Physician, Geisel School of Medicine Legal/ Regulatory Expert at Charla Stevens Consulting Senior Program Manager, National Safety Council President/CEO at Chameleon Group Research Project Manager at Dartmouth College, Course Director Director of Workforce Development at Recovery Friendly Workplace Legal/ Regulatory Expert at Sheehan Phinney Section Chief, Addiction Treatment Program, Dartmouth Health Education Director, Project ECHO at Dartmouth Health



Cannabis Pharmacology and Actions What Employers Need to Know

Kathleen Broglio, DNP, ANP-BC, ACHPN, CARN-AP, FPCN, FAANP, FAAHPM Nurse Practitioner Section of Palliative Medicine

Associate Professor of Medicine, Geisel School of Medicine at Dartmouth

Dartmouth Hitchcock Medical Center

kathleen.broglio@hitchcock.org



Disclosures

• I do not have any relevant financial disclosures



Objectives

- Discuss prevalence of cannabis use
- Describe reported reasons for therapeutic & recreational cannabis use
- Outline diversity of U. S. state laws for therapeutic & recreational cannabis use
- Describe cannabis pharmacology and routes of administration
- Discuss cannabis risks, side effects and impact on work performance




Cannabis has been in use for centuries

- 4000 B.C use China
- 450-200 B.C. Greco-Roman Use
- 1000 1464 A.D. Treatment for epilepsy
- 1850 U.S. Pharmacopeia -neuralgia, opioid addiction, alcoholism
- 1937 Marihuana Tax Act; Federal prohibition
- 1942 Removed from U. S. Pharmacopeia
- 1964 THC discovered
- 1970 CSA Schedule 1 (Recreational >> criminalization)
- 1988 CBD1 and CBD2 receptors discovered
- 2000 present Increased therapeutic use > Push for legalization



Cannabis Use in the U.S. 2023 Past year use

Figure 12. Past Year Illicit Drug Use: Among People Aged 12 or Older; 2023



Rx = prescription.

Note: The estimated numbers of past year users of different illicit drugs are not mutually exclusive because people could have used more than one type of illicit drug in the past year.

National Survey on Drug Use and Health, 2023

https://www.samhsa.gov/data/sites/default/files/reports/rpt47095/National%20Report/National%20Report/2023-nsduh-annual-national.pdfç



People use cannabis for a variety of reasons

- According to surveillance data 38% use for recreational, 33% for recreational and medical and 29% for medical only¹
- Young adults' motives for cannabis use were enjoyment/fun, conformity, experimentation, social enhancement, and relaxation²
- College students reported using cannabis for social facilitation, peer acceptance, emotional pain, and sex-seeking³
- In a small Canadian study of long term users the top reason for use was relaxation; other reasons included feeling good, enjoyment of media, medical use, inspiration, depression, anxiety, better sleep, and boredom⁴

¹Kurtzman & Wolff; *Drug Alcohol Depend;* 2021;226 <u>https://doi.org/10.1016/j.drugalcdep.2021.108880</u>; ²Lee et al.. Addict Behav. 2007;;32(7):1384-94. doi: 10.1016/j.addbeh.2006.09.010. ³Beck et alAddict Behav. 2009;34(9):764-8. doi: 10.1016/j.addbeh.2009.05.001; ⁴Hathaway. *Addiction Research & Theory*, 2003;*11*(6), 441–



People use cannabis to self-treat symptoms

27,169 respondents to 2018 online survey in U.S and Canada

- Self-reported ever symptom management use (27%)
- Higher in legal use states (34%) versus illegal use states (23%)
- Among reported reasons for symptom management:


Physical symptoms

Pain 53% Sleep 46% Headaches 35% Appetite 22% N/V 21%

Mental health symptoms Anxiety 52% Depression 40% PTSD/Trauma 17% SUD 11% Psychosis 4%



State cannabis policies are variable/changing




https://disa.com/marijuana-legality-by-state



Majority of **Americans** now support legalization of marijuana

U.S. public opinion on legalizing marijuana, 1969-2019

Do you think the use of marijuana should be made legal, or not? (%)




Note: No answer responses not shown, 2019 data from Pew Research Center's online American Trends Panel; prior data from telephone surveys. Data from 1969-1972 from Gallup; data from 1973-2008 from General Social Surveys. Source: Survey of U.S. adults conducted Sept. 3-15, 2019.

PEW RESEARCH CENTER

Only about one-in-ten Americans oppose marijuana legalization for medical or recreational uses

% who say marijuana ...

Total



Note: No answer responses not shown.

30-49

50-64

65+

Source: Survey of U.S. adults conducted Sept. 3-15, 2019.

PEW RESEARCH CENTER



Cannabis – What do we know?



Cannabis contains > 100 phytocannabinoids and > 600 chemical constituents

- Two most prevalent cannabinoids
 - Δ⁹-tetrahydrocannabinol (THC) psychoactive; anti-emetic, analgesia, appetite stimulation (discovered 1964)
 - Cannabidiol (CBD) –not psychoactive; anti-convulsant, anxiolysis, antiinflammatory
- Less studied cannabinoids & terpenes may contribute to effects
- NO standardization -Diverse strains bred and available
 - Very high THC concentrations are available
 - 1970s 3-5% THC typical -Vape products > 94% THC available in dispensary
 - Low THC, high CBD products and intermediate blends are available




Endogenous cannabinoid system

Endocannabinoids bind to cannabinoid receptors to exert diverse physiologic effects

- CB1 (primarily in nervous system)
- CB2 (primarily in immune system)

Physiologic roles in

- Nociception (pain regulation)
- Mood modulation including reward
- Cognition, learning & memory
- Energy balance, appetite




Implications: Limited understanding of the effects of exogenous (external) cannabinoids (like THC/CBD) on endogenous (internal) cannabinoid system

Volkow et al. *Annu Rev Pharmacol Toxicol*, 2017;57:285-308; DiMarzo & Piscitelli, The Endocannabinoid System & Its Modulation by Phytocannabinoids, Neurotherapeutics, 2015



Three pharmaceutical cannabis products are available in the U.S.



*CINV – chemotherapy induced nausea and vomiting; **MS multiple sclerosis



Cannabidiol (CBD) is widely available, but not well-regulated

Marketed indications not well studied







58 of 84 samples of CBD purchased online had mislabeled CBD content Bonn-Miller et al. JAMA. 2017;318 (17):1708-1709








What does the evidence show about cannabis therapeutic effects?





Cannabis evidence of effects is difficult to accurately determine



NASEM; 2017https://www.nap.edu/catalog/24625/the-health-effects-of-cannabis-and-cannabinoids-thecurrent-state; Abrams, *Eu J Int Med*, 2018, 49, 7-11



Cannabis: Evidence of Effects



• Chemotherapy-induced nausea & vomiting^{1,3}

Substantial or conclusive evidence for efficacy

- Subjective spasticity multiple sclerosis¹
- Epilepsy (Dravet and Lennox-Gastaut) CBD Epidiolex®⁴

• Short-term sleep^{1,5}

Moderate

 ¹ NASEM; 2017https://www.nap.edu/catalog/24625/the-health-effects-of-cannabis-and-cannabinoids-the-current-state; ²Nugent et al. 2017;167(5):319-331. ³Lichtman et al JPSM 2018 <u>https://doi.org/10.1016/j.jpainsymman.2017.09.001</u>
 ⁴Chow et al. Support Care in Cancer. 2020;28:2095–2103 https://doi.org/10.1007/s00520-019-05280-4 ; MacCallum & Russo. *Eur J Int Med.* 2018;49:12-19; ⁴ Privitera et al. *Epilepsia*. 2021;62(5):1130-1140 ⁵Bonaccorso. *Neurotoxicol*. <u>https://doi.org/10.1016/j.neuro.2019.08.002</u>



Cannabis: Evidence of Effects

 Appetite & weight loss in HIV/AIDS¹ Tourette symptoms¹ Anxiety symptoms in social anxiety disorders (CBD)^{1,2} PTSD symptoms¹ Limited Dementia¹ Cancer cachexia >appetite, > side effects, <QOL³ • Cancer – most literature preclinical^{4,5} Neurodegenerative disorders¹ Insufficient Irritable bowel syndrome¹ Addiction abstinence⁶ evidence

> ¹ NASEM. 2017;https://www.nap.edu/catalog/24625/the-health-effects-of-cannabis-and-cannabinoids-the-current-state; ²Wright. *Cannabis Cannabinoid Res* 2020. <u>https://pubmed.ncbi.nlm.nih.gov/32923656/</u>
> ³Wang et al. *Biomed Res Int.* 2019; <u>https://doi.org/10.1155/2019/2864384; ⁴</u>Abu-Amna et al. *Curr. Treat. Options in Oncol.* 2021;22:16 doi: 10.1007/s11864-020-00811; ⁵Goyal et al. *Comp Ther Med.* 2020; <u>https://doi.org/10.1016/j.ctim.2020.102336;</u> ⁶Bonaccorso. *Neurotoxicol.* <u>https://doi.org/10.1016/j.neuro.2019.08.002</u>



CBD may have efficacy for symptoms such as anxiety, insomnia, addiction, and mood, but highquality studies lacking

- Trials suggest that CBD may be effective for some anxiety¹
 - -Few human trials, mostly healthy males, social anxiety disorder²
- Preclinical, small clinical trials, anecdotal evidence
- Unclear side effects of CBD use due to lack of studies

Take home: Evidence is lacking, but people are experimenting with use of CBD for these conditions



Cannabis product formulations

Smoked	 Rapid onset of action 5-10 min Duration 2-4 hr Bioavailability 10-30%
Vaporization	 Rapid onset of action (peak 5-10 min) Metered dosing devices Risk of EVALI (e-cig/vaping associated lung injury)
Edibles	 Slower onset of action 60-180 min Duration 6-8 hours Bioavailability 6% extensive first pass effects
Transmucosal Sublingual	 More rapid onset of action than orals 15-45 minutes Duration 6-8 hours Pharmaceutical form (nabiximols) available
Transdermal Topical	 Variable onset - duration Highly lipophilic Slow onset, stable blood levels



Cannabis detection in urine drug testing varies

- Detection of THC in urine varies dependent on use
 - -Single use 3 days
 - -Moderate use (4x week) 5-7 days
 - -Chronic use (daily) 10-15 days
 - -Chronic heavy smoker >30 days



What are the adverse effects or potential harms of cannabis?





Reported THC adverse effects

Common reported adverse effects

- CNS
 - Drowsiness
 - Dizziness
 - Confusion
 - Mental Clouding
 - Slurred speech
- Physical
 - Tachycardia and hypotension
 - Nausea
 - Fatigue
 - Dry mouth
 - Cannabis hyperemesis syndrome



CBD also has adverse effects

- Adverse effects to CBD less studied except for FDA approved Epidiolex® for seizures
- Reported adverse effects include
 - Drowsiness/sedation
 - Mood changes
 - Interactions with prescription medications that may affect actions and cause toxicity
 - Liver toxicity
 - Reproductive and developmental effects

Take home: People are experimenting with CBD and may not be cognizant of potential adverse effects

Huestis et al. Curr Neuropharmacol. 2019;17(10):974-989. doi: 10.2174/1570159X17666190603171901. Cannabidiol (CBD) – Potential Harms, Side Effects, and Unknowns; What You Need to Know (And What We're Working to Find Out) About Products Containing Cannabis or Cannabisderived Compounds, Including CBD | FDA



Potential harms of cannabis use

Developmental changes in adolescents	ectual, motivational, maturational
	e studies show a significant correlation between THC blood concentrations and car crash risk
	d effects BP, Limited evidence - trigger MI, CVA, erbation COPD

National Institute of Drug Abuse – Cannabis https://nida.nih.gov/research-topics/cannabis-marijuana#short-term-health-cannabis Preuss et al. Front Psychiatry. 2021 28;12:643315. doi: 10.3389/fpsyt.2021.643315




Cannabis may affect work performance

- High quality studies evaluating effect of medical cannabis on workplace performance lacking¹
 - Reported 'adverse effects' such as sedation, nausea/vomiting, dizziness and euphoria could be associated with performance
- Canadian study showed 2-fold increase of injury risk for 'workplace cannabis use' but none for 'non-workplace use'²
- Case control study recreational marijuana legalization adoption and workplace injuries among younger workers aged 20 to 34 years
 - Recreational cannabis legalization adoption associated with 8.4% increase in injury³

¹O'Neill et al. *Workplace Health & Safety*. 2023;71(9):400-410. doi:10.1177/21650799; ² Carnide et al. *Canadian Journal of Public Health*. 2023;114(6):947-955. doi:10.17269/s41997-023-00795-0 ; Li et al.JAMA Health Forum. 2024 2;5(2):e235438. doi: 10.1001/jamahealthforum.2023.5438



Potential mental health harms of cannabis




National Academies of Science, Engineering & Medicine, 2017 Report; Substance Abuse and Mental Health Services Administrationhttps://www.samhsa.gov/substance-use/learn/marijuana/risks



Cannabis Use Disorder (CUD) & absenteeism

Figure 32. Marijuana Use Disorder, Prescription Pain Reliever Use Disorder, or Methamphetamine Use Disorder in the Past Year: Among People Aged 12 or Older; 2023



Dose-response relationship observed between CUD severity and skipping work²

National Survey on Drug Use and Health, 2023

https://www.samhsa.gov/data/sites/default/files/reports/rpt47095/National%20Report/National%20Report/2023-nsduh-annual-national.pdfc;

²Yang et al . American Journal of Preventive Medicine. 2024;67(6):803-810. doi:10.1016/j.amepre.2024.07.021



Some take away considerations

- Cannabis use is common in the U.S.
- People use cannabis for diverse reasons
- Laws and regulations are variable at state levels
- Cannabis use may impact individual well-being, work performance and workplace safety

Health Dartmouth Gelected References

- Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling Accuracy of Cannabidiol Extracts Sold Online. JAMA. 2017 Nov 7;318(17):1708-1709. doi: 10.1001/jama.2017.11909. PMID: 29114823; PMCID: PMC5818782.
- Carnide N, Landsman V, Lee H, Frone MR, Furlan AD, Smith PM. Workplace and non-workplace cannabis use and the risk of workplace injury: Findings from a longitudinal study of Canadian workers. *Canadian journal of public health*. 2023;114(6):947-955. doi:10.17269/s41997-023-00795-0
- DISA. Marijuana legality by State. Last updated 4/28/2025. https://disa.com/marijuana-legality-by-state
- Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busardò FP. Cannabidiol Adverse Effects and Toxicity. Curr Neuropharmacol. 2019;17(10):974-989. doi: 10.2174/1570159X17666190603171901. PMID: 31161980; PMCID: PMC7052834.
- Leung J, Chan G, Stjepanović D, Chung JYC, Hall W, Hammond D. Prevalence and self-reported reasons of cannabis use for medical purposes in USA and Canada. Psychopharmacology (Berl). 2022https://pmc.ncbi.nlm.nih.gov/articles/PMC9110511
- Li L, Liang Y, Sabia JJ, Dave DM. Recreational Marijuana Legalization and Workplace Injuries Among Younger Workers. JAMA Health Forum. 2024 Feb 2;5(2):e235438. doi: 10.1001/jamahealthforum.2023.5438. PMID: 38393722; PMCID: PMC10891478
- O'Neill V, Karanikas N, Sav A, Murphy P. Medicinal Cannabis and Implications for Workplace Health and Safety: Scoping Review of Systematic Reviews. *Workplace health & safety*. 2023;71(9):400-410. doi:10.1177/21650799
- Preuss UW, Huestis MA, Schneider M, Hermann D, Lutz B, Hasan A, Kambeitz J, Wong JWM, Hoch E. Cannabis Use and Car Crashes: A Review. Front Psychiatry. 2021 May 28;12:643315. doi: 10.3389/fpsyt.2021.643315. PMID: 34122176; PMCID: PMC8195290.
- Substance Abuse and Mental Health Services Administration. (2024). Key substance use and mental health indicators in the United States: Results from the 2023 National Survey on Drug Use and Health (HHS Publication No. PEP24-07-021, NSDUH Series H-59). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. <u>https://www.samhsa.gov/data/report/2023-nsduh-annual-national-report</u>
- Substance Abuse and Mental Health Services Administration. Know the risks, effects and side effects of marijuana. <u>https://www.samhsa.gov/substance-use/learn/marijuana/risks</u> (updated 11/2024)
- Substance Abuse and Mental Health Services Administration. Cannabidiol (CBD) Potential harms, side effects and unknowns. <u>Cannabidiol (CBD) Potential Harms</u>, <u>Side Effects</u>, and <u>Unknowns</u> (updated 2/2023)
- Yang KH, Mueller L, El-Shahawy O, Palamar JJ. Cannabis Use, Use Disorder, and Workplace Absenteeism in the U.S., 2021–2022. American Journal of Preventive Medicine. 2024;67(6):803-810. doi:10.1016/j.amepre.2024.07.021







